Product
QTORIN 3.9% Rapamycin Anhydrous
Aliases
QTORIN 3.9% Rapamycin Anhydrous Gel
1 clinical trial
1 indication
Indication
Microcystic Lymphatic MalformationClinical trial
A Multicenter, Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsStatus: Not yet recruiting, Estimated PCD: 2025-12-01